Regeneron Expands its Existing Collaboration with HHS’BARDA to Develop Antibody Therapies for Coronavirus

 Regeneron Expands its Existing Collaboration with HHS’BARDA to Develop Antibody Therapies for Coronavirus

Regeneron Expands its Existing Collaboration with HHS’BARDA to Develop Antibody Therapies for Coronavirus

Shots:

  • The collaboration leverages Regeneron’s VelociSuite technologies including the VelocImmune platform to develop mAb as monothx. or in combination to treat coronavirus (2019-nCoV)
  • In 2017, HHS and Regeneron collaborated for discovery, research, development and manufacturing of an Abs targeting up to 10 pathogens including influenza virus and 2019-nCoV
  • Regeneron’s VelociSuite technologies including the VelocImmune platform utilizes a unique genetically engineered mouse with a humanized immune system, accelerating swift identification, preclinical validation and development Ab therapies

Click here ­to­ read full press release/ article | Ref: Regeneron  | Image: The Pharma Letter

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post